Holders — by stockHoldings — by fund
Soleus Capital Management, L.P.
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001802630
$2.90B
disclosed book value
97
positions
12%
largest position share
Positions, as of 2026-06-30
top 97 of 97 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | KRYSKRYSTAL BIOTECH INC | 939,254 | $349.1M | 12% |
| 2 | CELCCELCUITY INC | 1.7M | $178.3M | 6.1% |
| 3 | TGTXTG THERAPEUTICS INC | 2.9M | $160.9M | 5.5% |
| 4 | PODDINSULET CORP | 1.0M | $159.7M | 5.5% |
| 5 | NVCRNOVOCURE LTD | 9.9M | $150.2M | 5.2% |
| 6 | UTHRUNITED THERAPEUTICS CORP DEL | 225,587 | $122.2M | 4.2% |
| 7 | INSPINSPIRE MED SYS INC | 1.9M | $86.2M | 3% |
| 8 | RIGLRIGEL PHARMACEUTICALS INC | 1.8M | $72.1M | 2.5% |
| 9 | ANIPANI PHARMACEUTICALS INC | 867,760 | $71.8M | 2.5% |
| 10 | BBNXBETA BIONICS INC | 4.4M | $68.8M | 2.4% |
| 11 | VCELVERICEL CORP | 1.5M | $64.9M | 2.2% |
| 12 | PRAXPRAXIS PRECISION MEDICINES I | 177,517 | $59.4M | 2% |
| 13 | GERNGERON CORP | 42.8M | $54.8M | 1.9% |
| 14 | ALKSALKERMES PLC | 1.0M | $53.9M | 1.9% |
| 15 | ERASERASCA INC | 2.7M | $49.5M | 1.7% |
| 16 | NPCENEUROPACE INC | 2.9M | $46.3M | 1.6% |
| 17 | PGNYPROGYNY INC | 1.6M | $46.2M | 1.6% |
| 18 | INDVINDIVIOR PHARMACEUTICALS INC | 1.1M | $43.7M | 1.5% |
| 19 | PBLSPARABILIS MEDICINES INC | 1.5M | $40.1M | 1.4% |
| 20 | FOCLEDAP TMS S A | 7.3M | $37.9M | 1.3% |
| 21 | GMEDGLOBUS MED INC | 468,922 | $37.0M | 1.3% |
| 22 | RCUSARCUS BIOSCIENCES INC | 1.2M | $36.0M | 1.2% |
| 23 | SNDXSYNDAX PHARMACEUTICALS INC | 1.6M | $35.6M | 1.2% |
| 24 | NRIXNURIX THERAPEUTICS INC | 1.5M | $35.5M | 1.2% |
| 25 | LEGNLEGEND BIOTECH CORP | 1.2M | $34.8M | 1.2% |
| 26 | JBIOJADE BIOSCIENCES INC | 1.6M | $34.5M | 1.2% |
| 27 | UNHUNITEDHEALTH GROUP INC | 80,000 | $33.3M | 1.1% |
| 28 | AVTXAVALO THERAPEUTICS INC | 1.7M | $30.6M | 1.1% |
| 29 | URGNUROGEN PHARMA LTD | 829,810 | $30.5M | 1.1% |
| 30 | MBXMBX BIOSCIENCES INC | 515,279 | $28.4M | 1% |
| 31 | PALIPALISADE BIO INC | 13.1M | $27.3M | 0.9% |
| 32 | PHVSPHARVARIS N V | 730,907 | $25.3M | 0.9% |
| 33 | ORGOORGANOGENESIS HLDGS INC | 10.1M | $24.6M | 0.8% |
| 34 | SUPNSUPERNUS PHARMACEUTICALS | 520,000 | $24.2M | 0.8% |
| 35 | PRCTPROCEPT BIOROBOTICS CORP | 1.0M | $22.6M | 0.8% |
| 36 | TNGXTANGO THERAPEUTICS INC | 709,000 | $22.2M | 0.8% |
| 37 | IKTINHIBIKASE THERAPEUTICS INC | 10.9M | $22.1M | 0.8% |
| 38 | TRVITREVI THERAPEUTICS INC | 1.2M | $22.0M | 0.8% |
| 39 | BMRNBIOMARIN PHARMACEUTICAL INC | 375,572 | $21.5M | 0.7% |
| 40 | LIVNLIVANOVA PLC | 254,957 | $21.0M | 0.7% |
| 41 | ARGXARGENX SE | 19,955 | $18.5M | 0.6% |
| 42 | NVCTNUVECTIS PHARMA INC | 1.0M | $18.4M | 0.6% |
| 43 | CAPRCAPRICOR THERAPEUTICS INC | 761,737 | $18.3M | 0.6% |
| 44 | EWTXEDGEWISE THERAPEUTICS INC | 450,889 | $18.3M | 0.6% |
| 45 | PRLDPRELUDE THERAPEUTICS INC | 3.4M | $18.0M | 0.6% |
| 46 | XENEXENON PHARMACEUTICALS INC | 267,000 | $16.1M | 0.6% |
| 47 | CCCCC4 THERAPEUTICS INC | 3.4M | $15.8M | 0.5% |
| 48 | KNSAKINIKSA PHARMACEUTICALS INTL | 246,353 | $15.8M | 0.5% |
| 49 | KIDSORTHOPEDIATRICS CORP | 732,144 | $14.0M | 0.5% |
| 50 | AVLNAVALYN PHARMACEUTICALS INC | 419,000 | $13.8M | 0.5% |
| 51 | BDSXBIODESIX INC | 585,958 | $13.2M | 0.5% |
| 52 | SYRESPYRE THERAPEUTICS INC | 147,000 | $13.1M | 0.4% |
| 53 | TWSTTWIST BIOSCIENCE CORP | 104,629 | $10.8M | 0.4% |
| 54 | VIRVIR BIOTECHNOLOGY INC | 1.0M | $10.2M | 0.4% |
| 55 | ALNYALNYLAM PHARMACEUTICALS INC | 33,050 | $9.9M | 0.3% |
| 56 | IMVTIMMUNOVANT INC | 252,000 | $9.7M | 0.3% |
| 57 | INSMINSMED INC | 90,250 | $9.6M | 0.3% |
| 58 | SEPNSEPTERNA INC | 275,000 | $9.2M | 0.3% |
| 59 | SOPHSOPHIA GENETICS SA | 1.6M | $9.0M | 0.3% |
| 60 | NKTRNEKTAR THERAPEUTICS | 128,362 | $9.0M | 0.3% |
| 61 | MIRMMIRUM PHARMACEUTICALS INC | 75,000 | $8.8M | 0.3% |
| 62 | AORTARTIVION INC | 388,000 | $8.7M | 0.3% |
| 63 | TNDMTANDEM DIABETES CARE INC | 575,000 | $8.7M | 0.3% |
| 64 | ELVNENLIVEN THERAPEUTICS INC | 165,677 | $8.4M | 0.3% |
| 65 | SIONSIONNA THERAPEUTICS INC | 177,687 | $7.8M | 0.3% |
| 66 | BLTEBELITE BIO INC | 50,524 | $7.8M | 0.3% |
| 67 | CERSCERUS CORP | 2.5M | $7.3M | 0.3% |
| 68 | SLNSILENCE THERAPEUTICS PLC | 630,000 | $6.9M | 0.2% |
| 69 | IMUXIMMUNIC INC | 450,000 | $6.9M | 0.2% |
| 70 | IVVDINVIVYD INC | 7.7M | $6.7M | 0.2% |
| 71 | MRKMERCK & CO INC | 50,000 | $6.4M | 0.2% |
| 72 | RLMDRELMADA THERAPEUTICS INC | 842,106 | $5.8M | 0.2% |
| 73 | GPCRSTRUCTURE THERAPEUTICS INC | 107,000 | $5.7M | 0.2% |
| 74 | EOLSEVOLUS INC | 822,428 | $5.7M | 0.2% |
| 75 | ANLADLAI NORTYE LTD | 405,523 | $4.7M | 0.2% |
| 76 | ZNTLZENTALIS PHARMACEUTICALS INC | 950,000 | $4.6M | 0.2% |
| 77 | KPTIKARYOPHARM THERAPEUTICS INC | 440,000 | $4.3M | 0.1% |
| 78 | CNTXCONTEXT THERAPEUTICS INC | 7.1M | $3.9M | 0.1% |
| 79 | LUNGPULMONX CORP | 2.8M | $3.6M | 0.1% |
| 80 | SABSSAB BIOTHERAPEUTICS INC | 900,000 | $3.5M | 0.1% |
| 81 | TECXTECTONIC THERAPEUTIC INC | 101,684 | $3.5M | 0.1% |
| 82 | AXGNAXOGEN INC | 57,036 | $2.6M | 0.1% |
| 83 | MSLESATELLOS BIOSCIENCE INC | 314,359 | $2.4M | 0.1% |
| 84 | AVBPARRIVENT BIOPHARMA INC | 50,000 | $1.7M | 0.1% |
| 85 | CORTCORCEPT THERAPEUTICS INC | 19,653 | $1.7M | 0.1% |
| 86 | SLDBSOLID BIOSCIENCES INC | 150,000 | $1.5M | 0.1% |
| 87 | VCYTVERACYTE INC | 25,000 | $1.5M | 0.1% |
| 88 | CGEMCULLINAN THERAPEUTICS INC | 50,000 | $910,500 | 0% |
| 89 | NSPRINSPIREMD INC | 1.0M | $732,100 | 0% |
| 90 | WGSGENEDX HOLDINGS CORP | 10,000 | $686,500 | 0% |
| 91 | IOVAIOVANCE BIOTHERAPEUTICS INC | 150,000 | $624,000 | 0% |
| 92 | LRMRLARIMAR THERAPEUTICS INC | 188,102 | $573,711 | 0% |
| 93 | CGONCG ONCOLOGY INC | 5,000 | $355,250 | 0% |
| 94 | QNRXQUOIN PHARMACEUTICALS LTD | 72,730 | $352,013 | 0% |
| 95 | EQEQUILLIUM INC | 90,000 | $288,000 | 0% |
| 96 | NTRANATERA INC | 1,000 | $271,450 | 0% |
| 97 | NEONEOGENOMICS INC | 10,000 | $145,900 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.